European HealthTech this week is characterised by AI‑heavy care models preparing for the EU AI Act, continued investor focus on preventive and platform plays, and early‑stage funding/grant activity positioning startups for 2026–27 scale‑up. European MedTech this week is dominated by regulatory moves in Brussels, tightening timelines ahead of the 2026 MDR/IVDR and EUDAMED deadlines, alongside positioning by industry and investors for an “industrial maturity” phase rather than